These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4783767)

  • 21. Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging.
    Takano M; Sasaki N; Kita T; Kudoh K; Fujii K; Yoshikawa T; Kato M; Hirata J; Furuya K; Tsuda H; Kikuchi Y
    Oncol Rep; 2008 May; 19(5):1259-64. PubMed ID: 18425385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carcinoma of the ovary.
    Heintz AP; Odicino F; Maisonneuve P; Beller U; Benedet JL; Creasman WT; Ngan HY; Sideri M; Pecorelli S
    J Epidemiol Biostat; 2001; 6(1):107-38. PubMed ID: 11385772
    [No Abstract]   [Full Text] [Related]  

  • 23. Association of lymphadenectomy and survival in stage I ovarian cancer patients.
    Chan JK; Munro EG; Cheung MK; Husain A; Teng NN; Berek JS; Osann K
    Obstet Gynecol; 2007 Jan; 109(1):12-9. PubMed ID: 17197582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coexisting endometrial and ovarian carcinomas: a retrospective clinicopathological study.
    Caldarella A; Crocetti E; Taddei GL; Paci E
    Pathol Res Pract; 2008; 204(9):643-8. PubMed ID: 18472354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Factors that influence the late treatment results in ovarian cancer].
    Petrov AM
    Vopr Onkol; 1980; 26(5):32-6. PubMed ID: 7385713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.
    Diefenbach CS; Soslow RA; Iasonos A; Linkov I; Hedvat C; Bonham L; Singer J; Barakat RR; Aghajanian C; Dupont J
    Cancer; 2006 Oct; 107(7):1511-9. PubMed ID: 16944535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epithelial ovarian tumors of borderline malignancy: long-term follow-up.
    Casey AC; Bell DA; Lage JM; Fuller AF; Nikrui N; Rice LW
    Gynecol Oncol; 1993 Sep; 50(3):316-22. PubMed ID: 8406194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms.
    Sainz de la Cuesta R; Goff BA; Fuller AF; Nikrui N; Eichhorn JH; Rice LW
    Obstet Gynecol; 1994 Jul; 84(1):1-7. PubMed ID: 8008300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesonephroid tumors of the ovary. Clinical and histopathologic studies.
    Aure JC; Høeg K; Kolstad P
    Obstet Gynecol; 1971 Jun; 37(6):860-7. PubMed ID: 4378209
    [No Abstract]   [Full Text] [Related]  

  • 32. Ovarian metastases from colorectal cancer: a clinicopathological analysis of 103 patients.
    Kim DD; Park IJ; Kim HC; Yu CS; Kim JC
    Colorectal Dis; 2009 Jan; 11(1):32-8. PubMed ID: 18462217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
    Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
    Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Seminoma of the ovary. Clincopathological study. The role of radiotherapy in treatment based upon a series of 31 cases (author's tranls)].
    Papillon J; Chassard JL; Gérard J; Bonnevie R; Baudot A
    J Radiol Electrol Med Nucl; 1976 Nov; 57(11):771-81. PubMed ID: 1011176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of P-32 in stage III epithelial carcinoma of the ovary.
    Spanos WJ; Day T; Jose B; Paris K; Lindberg RD
    Gynecol Oncol; 1994 Jul; 54(1):35-9. PubMed ID: 8020836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Late results of the treatment of I stage malignant ovarian tumors depending on a number of factors].
    Mar'ina LA
    Vopr Onkol; 1977; 23(11):60-5. PubMed ID: 595517
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer.
    Ramus SJ; Elmasry K; Luo Z; Gammerman A; Lu K; Ayhan A; Singh N; McCluggage WG; Jacobs IJ; Whittaker JC; Gayther SA
    Clin Cancer Res; 2008 Sep; 14(18):5840-8. PubMed ID: 18794095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of ovarian cancer patients who underwent incomplete surgical staging.
    Panprom P; Lertkhachonsuk R
    J Med Assoc Thai; 2008 Sep; 91(9):1323-30. PubMed ID: 18843859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Radiotherapy and ovarian cancer. Experiences up to now and current concepts of the Norwegian Radium Hospital].
    Kjorstad KE
    Gynakologe; 1986 Sep; 19(3):170-7. PubMed ID: 3770528
    [No Abstract]   [Full Text] [Related]  

  • 40. Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
    Bolat F; Gumurdulu D; Erkanli S; Kayaselcuk F; Zeren H; Ali Vardar M; Kuscu E
    Pathol Res Pract; 2008; 204(6):379-87. PubMed ID: 18343598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.